Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Anushka Mukherjee

What Are Wall Street Analysts' Target Price for Insulet Stock?

Acton, Massachusetts-based Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. Valued at a market capitalization of $17.1 billion, the company offers the Omnipod platform, comprising the Omnipod 5 automated insulin delivery system and the Omnipod DASH insulin management system.

The company's shares have underperformed the broader market over the past year and in 2026. PODD stock has declined 12.2% over the past 52 weeks and 13.3% on a YTD basis. In comparison, the S&P 500 Index ($SPX) has returned 11.9% over the past year and declined marginally in 2026.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.